Stock GLPG GALAPAGOS NV
Add to a list
To use this feature you must be a member
Log inSign up
Inactive Instrument

Other languages Galapagos NV Euronext Bruxelles

Equities

GLPG

BE0003818359

End-of-day quote Euronext Bruxelles
Other stock markets
- - Intraday chart for Galapagos NV
31/05 Galapagos, Adaptimmune to Jointly Develop Head, Neck Cancer Treatment MT
31/05 Galapagos, Adaptimmune Therapeutics Team Up to Evaluate Head and Neck Cancer Drug MT

Other languages

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Galapagos, Adaptimmune to Jointly Develop Head, Neck Cancer Treatment
Galapagos, Adaptimmune Therapeutics Team Up to Evaluate Head and Neck Cancer Drug
Galapagos : Galapagos and Adaptimmune sign clinical collaboration agreement with an option to exclusively license Adaptimmune’s TCR T cell therapy candidate, uza cel, in head & neck cancer and potential future so
Galapagos and Adaptimmune sign clinical collaboration agreement with an option to exclusively license Adaptimmune’s TCR T-cell therapy candidate, uza-cel, in head & neck cancer and potential future solid tumor indications
Galapagos : Galapagos creates new subscription right plans
Galapagos creates new subscription right plans
Galapagos Partners with Blood Centers of America to Decentralize CAR-T Cell Therapy Manufacture
Galapagos and Blood Centers of America announce strategic collaboration to accelerate Galapagos’ decentralized CAR-T manufacturing network in the U.S.
Galapagos and Blood Centers of America Announce Strategic Collaboration to Accelerate Galapagos? Decentralized Car-T Manufacturing Network in the U.S
Transcript : Galapagos NV, Q1 2024 Earnings Call, May 03, 2024
Galapagos : Galapagos reports first quarter 2024 financial results
Galapagos reports first quarter 2024 financial results  
Galapagos NV Reports Earnings Results for the First Quarter Ended March 31, 2024
Galapagos : Galapagos’ shareholders adopt all resolutions proposed by the Board of Directors at the Annual and Extraordinary Shareholders Meetings 2024
Galapagos’ shareholders adopt all resolutions proposed by the Board of Directors at the Annual and Extraordinary Shareholders Meetings 2024
Galapagos Showcases Innovative Approach in Hematological Cancer Care with Clinical and Translational Data Presentations at EBMT Congress 2024
Galapagos : Galapagos showcases innovative approach in hematological cancer care with clinical and translational data presentations at EBMT congress 2024
Galapagos showcases innovative approach in hematological cancer care with clinical and translational data presentations at EBMT congress 2024
Galapagos : Galapagos publishes 2023 annual report and announces Annual and Extraordinary Shareholders’ Meetings
Galapagos publishes 2023 annual report and announces Annual and Extraordinary Shareholders’ Meetings
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. GLPG Stock
  4. GLPG Stock
  5. News Galapagos NV
  6. Other languages